American physicians strongly support AMA recommendations for ending the nation’s opioid epidemic.
Those recommendations include improving state Prescription Drug Monitoring Programs (PDMPs), enhancing physician education, and removing barriers to care, especially to use of naloxone.
A survey conducted by the AMA Task Force to Reduce Opioid Abuse indicated that 87 percent of responding physicians believe PDMPs help physicians become more informed about a patient’s prescription history. The survey also found that to further enhance this as a resource, physicians said PDMPs need to be integrated with electronic health records, provide real-time data, and add other key features to make them more useful.
(The survey was conducted for the AMA by TNS Global Research between November 13, 2015, and November 23, 2015. The sample size was 2,130 practicing U.S. physicians who provide a minimum of 20 hours a week in direct patient care, have a current DEA license to prescribe Schedule II controlled substances, and prescribe opioids on a weekly or more frequent basis. The sample included all practice settings and regions in the United States.)
“If a physician is considering prescribing an opioid—whether for acute or chronic pain—we strongly encourage physicians to ensure that they are current in their knowledge and training as to when an opioid is appropriate—and when it is not,” said AMA President Steven J. Stack, M.D., in a statement. “This new survey helps underscore that medical societies must be leaders in providing the best resources possible to our colleagues in every state and for every specialty, both for appropriate opioid prescribing and in urging physicians to register for and use PDMPs.”
In related news, the AMA and leaders of the National Governors Association signed a joint statement calling for concerted action to end the nation’s opioid epidemic (see box on page 32).
The AMA survey also found that a majority of respondents have taken continuing medical education (CME) on safe opioid prescribing (68 percent) and pain management with opioid alternatives (55 percent). Moreover, the survey found that physicians want more practice-specific and specialty-specific education—1 in 4 physicians said that CME on these issues either was not readily available for their specialty or did not directly address their practice needs.
Only 15 percent of the respondents had taken courses on medication-assisted treatment (MAT). The AMA Task Force to Reduce Opioid Abuse has made increasing access to MAT a priority, and several medical organizations, including APA, offer training in MAT (see story on page 37).
In addition, the survey found strong support for increasing access to naloxone. More than 80 percent of the respondents said that naloxone should be available to a patient via a standing order or collaborative practice agreement with a pharmacist.
The AMA has model legislation that includes support for standing orders, and the AMA also has supported more than 20 state laws that increase access to naloxone in the community. Additionally, the AMA believes that it is essential that pharmaceutical companies and health plans ensure easy, reliable, and affordable access to this lifesaving medication.
“The next step to help increase access to naloxone is for physicians to co-prescribe this lifesaving medication to patients at risk of overdose,” said Stack. “Just as we would co-prescribe an epi-pen to a person at risk for a life-threatening allergic reaction, we should co-prescribe naloxone to a patient at risk for overdose.” ■
Information about the AMA survey can be accessed
here. The joint NGA-AMA statement is available
here.